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Abstract
Objectives: The most frequent presentation of chemotherapy-related toxicity in colorectal liver metas-
tases (CRLM) is sinusoidal obstruction syndrome (SOS). The purpose of the present study was to identify
preoperative factors predictive of SOS and to establish associations between type of chemotherapy and
severity of SOS.
Methods: A retrospective study was carried out in a tertiary academic referral hospital. Patients suffering
from CRLM who had undergone resection of at least one liver segment were included. Grading of SOS
on the non-tumoral liver parenchyma was accomplished according to the Rubbia-Brandt criteria. A total
of 151 patients were enrolled and divided into four groups according to the severity of SOS (grades 0–3).
Results: Multivariate analysis identified oxaliplatin and 5-fluorouracil as chemotherapeutic agents
responsible for severe SOS lesions (P < 0.001 and P = 0.005, respectively). Bevacizumab was identified
as having a protective effect against the occurrence of SOS lesions (P = 0.005). Univariate analysis
identified the score on the aspartate aminotransferase : platelets ratio index (APRI) as the most significant
biological factor predictive of severe SOS lesions. Splenomegaly is also significantly associated with the
occurrence of severe SOS lesions.
Conclusions: The APRI score and splenomegaly are effective as factors predictive of SOS. Bevacizu-
mab has a protective effect against SOS.
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Introduction
Chemotherapy is increasingly used as part of an integrated mul-
timodal approach to treating colorectal liver metastases (CRLM).
Tumour response rates have improved tremendously over recent
decades and now reach 80% as a result of the combination of
current chemotherapeutic agents including oxaliplatin and iri-
notecan and, more recently, biological agents such as cetuximab
and bevacizumab.1–4 These effective chemotherapies are increas-
ingly used prior to liver surgery for CRLM. Initially, preoperative
chemotherapy was administered in unresectable patients and suc-
ceeded in converting 9–40% of initially unresectable metastases to
resectable status.2,5 In current practice, preoperative chemo-
therapy is often administered to patients with resectable CRLM to
reduce the risk for tumour relapse3,6 and to identify patients in
whom disease will progress rapidly during chemotherapy. The
latter factor helps to avoid futile hepatic surgery being offered to
patients with poor prognoses.7 Some chemotherapeutic agents,
especially oxaliplatin-based agents, may have significant toxicity
This manuscript was presented at the 10th World IHPBA Congress, Paris,
1–5 July 2012.
DOI:10.1111/hpb.12047 HPB
HPB 2013, 15, 858–864 © 2013 International Hepato-Pancreato-Biliary Association
on normal hepatic parenchyma. Indeed, sinusoidal obstruction
syndrome (SOS) was first reported in 2004 by Rubbia-Brandt
et al.8 Since then, several clinical series have confirmed the pres-
ence of SOS lesions in patients treated with oxaliplatin and have
reported their potential clinical impact in the context of liver
surgery, including an increased risk for intraoperative bleeding
and postoperative liver insufficiency.9–13 In view of these potential
adverse effects, a more cautious approach to the preoperative
administration of chemotherapy has been employed. Increased
use of preoperative liver function tests, such as the indocyanine
green (ICG) test, preoperative liver biopsy14,15 and portal vein
embolization (PVE)15,16 has been proposed. Preoperative factors
predictive of SOS may be very helpful in the identification and
better selection of patients who are at risk for severe SOS. The
primary objective of the present study was to evaluate whether
preoperative biological factors, liver function tests and scoring
systems, respectively, were able to predict the occurrence of SOS
lesions. The secondary objective was to evaluate the potential
protective effect of bevacizumab against the occurrence of SOS
lesions.
Materials and methods
Patients
Between January 2000 and January 2011, 302 patients underwent
liver resection for CRLM in the Department of Abdominal
Surgery and Transplantation, Saint-Luc University Hospital, Brus-
sels, Belgium.
A retrospective review of data for those patients was conducted.
A total of 151 (50%) patients were included for further analysis
because they were identified as having undergone resection of at
least one liver segment and thus to have provided enough non-
tumoral liver tissue to facilitate a representative pathological analy-
sis. Grading of SOS on the non-tumoral liver parenchyma was
accomplished according to the criteria defined by Rubbia-Brandt
et al.8 Percutaneous PVE was carried out when the future liver
remnant was estimated to represent <30% of the total liver volume
or when it represented <1% of the patient’s body weight. The size of
the spleen was measured on preoperative magnetic resonance
imaging or computed tomography and was recorded. Splenom-
egaly was defined as a spleen major axis (craniocaudal) of >13 cm.17
Chemotherapy
Only chemotherapy administered within 6 months prior to liver
surgery was taken into consideration. Type, duration and the
interval between the administration of chemotherapy and liver
resection were recorded. Liver resection was performed at least 4
weeks after the last course of chemotherapy and at least 6 weeks
after the last administration of bevacizumab.
Preoperative assessment of liver function
Preoperative serum biologic data including platelet count, aspar-
tate aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (AP), g-glutamyl-transferase (GGT) and
direct bilirubin were collected. An ICG test, currently used to
assess liver function,18,19 was used in the majority of patients and
especially in those who underwent a major hepatectomy (resec-
tion of at least three liver segments) or those who received
more than three courses of chemotherapy. Data on ICG test
values were missing in 27 patients who underwent minor hepa-
tectomy. The AST : platelet ratio index (APRI) score and a score
based on the relationships among four regression coefficients
(Fib-4 score), initially used to predict fibrosis in patients suffer-
ing from hepatitis C, were calculated according to the appro-
priate formulae:20–22 APRI score
AST level U L ULN
Platelet count L
=
( )
( ) ×10 1009
and FIB- score
age years AST U L
Platelet L ALT U L
4
109
=
( )× ( )
( )× ( ) .
Pathological examination
All formalin-fixed, paraffin-embedded archival samples of the
non-tumoral liver parenchyma were reviewed by one pathologist
who was unaware of the clinical and biological patient data. Mor-
phological analyses were based on haematoxylin and eosin (H&E)
and reticulin-stained slides. Sinusoidal congestion was graded
from 0 to 3 according to the severity of findings, as proposed in the
original publication by Rubbia-Brandt et al.,8 in which grade 0 =
absent, grade 1 = mild (one third of the lobule is affected), grade
2 = moderate (two thirds of the lobule are affected), and grade 3 =
severe (the whole lobule is affected). Nodular regenerative hyper-
plasia (NRH) was defined as distinct nodular hyperplasia on H&E
staining, clarified by reticulin staining, and was considered in the
analysis of the present results as disease coexistent with SOS.9,16
Statistics
Statistical analyses for comparisons were performed using the
Yates trend test.
Univariate or multivariate regressions for ordered categorical
data were used to determine the relationships between the severity
of SOS lesions and preoperative dichotomic variables, including
gender, PVE, chemotherapy agents and splenomegaly.23 Ordinary
univariate and multivariate regressions were used to determine
the relationships between continuous variables (including age,
serum platelet count, AST, ALT, GGT, AP, direct bilirubin, and liver
function evaluation tests such as the ICG test, APRI and Fib-4
scores) and severity of SOS lesions. A P-value of <0.05 was con-
sidered to indicate statistical significance.
Results
Patients
A total of 151 patients met the criteria for inclusion and thus their
data were included for analysis. Thirty-five patients (Group 1) did
not exhibit any SOS lesions, 49 patients (Group 2) presented mild
(grade 1) SOS lesions, 51 patients (Group 3) presented moderate
(grade 2) SOS lesions and 16 patients (Group 4) demonstrated
severe (grade 3) SOS lesions. Four patients with SOS grade 2 and
HPB 859
HPB 2013, 15, 858–864 © 2013 International Hepato-Pancreato-Biliary Association
one patient with SOS grade 3 presented coexistent NRH (7%).
Univariate analysis of demographic and clinical features as poten-
tially predictive factors of SOS injury is detailed in Table 1. Two
patients presenting with splenomegaly had NRH.
Chemotherapy
Data on chemotherapeutic agents are detailed in Table 1. Multi-
variate analysis performed on chemotherapy data showed that the
administration of either 5-fluorouracil (5-FU) (P < 0.001) or
oxaliplatin-based chemotherapy (P = 0.005) was a significant
independent factor predicting the presence of SOS lesions.
Biological variables
Results of univariate analysis for biological predictive factors are
shown in Table 2. Although median preoperative platelet counts
were significantly lower in Groups 3 and 4 than in Groups 1 and 2,
values remained within the normal range. Four of the 35 patients
in Group 1 had a slightly elevated ICG test (10.8–13.8%) and two
of 35 patients had an APRI score of >0.36, but none of the 35
patients in Group 1 had an abnormal preoperative platelet count
(<150 000/mm3). By contrast, abnormal platelet counts were
observed in seven of 49 (14%) patients in Group 2, 11 of 51 (22%)
patients in Group 3 and two of 16 (13%) patients in Group 4
(P = 0.029). Among patients for whom data on preoperative ICG
tests were available, abnormal ICG test values (>10%) were found
in four of 35 patients in Group 1, 11 of 49 patients in Group 2, 15
of 51 patients in Group 3 and five of 16 patients in Group 4
(P = 0.044). Of the five patients presenting with NRH (3%), three
had an abnormal ICG test (values of 13%, 13% and 29%, respec-
tively) and two presented both abnormal platelet values (94 ¥ 109/l
and 126 ¥ 109/l, respectively) and high APRI scores (0.56 and 1.77,
respectively) and Fib-4 scores (4.32 and 4.50, respectively). Abnor-
mal direct bilirubin and GGT values were found in only two
patients with NRH.
Data regarding biological factors that were significantly predic-
tive of SOS and scores in univariate analysis are illustrated in Fig. 1.
Bevacizumab and sinusoidal lesions
Data on bevacizumab are detailed in Tables 1 and 3.
Prevalences of grade 2 and 3 SOS lesions (Groups 3 and 4)
were significantly lower when bevacizumab was administered
(P = 0.005). Moreover, the prevalence of severe SOS lesions was
significantly higher in the group of patients who received preop-
erative oxaliplatin-based chemotherapy alone compared with
Table 1 Univariate analysis of demographic and clinical features and chemotherapeutic agents that represent factors predictive of the
occurrence of sinusoidal obstruction syndrome (SOS)
Group 1 Group 2 Group 3 Group 4 P-value
(SOS
grade 0,
n = 35)
(SOS
grade 1,
n = 49)
(SOS
grade 2,
n = 51)
(SOS
grade 3,
n = 16)
Age, years, mean (range) 64 (27–75) 65 (14–82) 65 (47–86) 64 (40–73) 0.130
Gender, male/female, n 21/14 19/30 26/25 9/7 0.890
Portal vein embolization, n (%) 9 (26%) 20 (41%) 20 (39%) 7 (44%) 0.200
Splenomegaly (>13 cm), n (%) 0 0 2 (4%) 2 (13%) 0.009
Chemotherapy, n (%) 24 (69%) 45 (92%) 46 (90%) 15 (94%) 0.007
FOLFOX, patients, n (%) 11 (31%) 28 (57%) 29 (57%) 9 (56%) 0.005
Number of cycles, mean (range) 6 (3–12) 8 (3–21) 9 (2–18) 7 (4–24) 0.210
Interval between chemotherapy and surgery, months, mean (range) 1 (1–6) 2 (1–6) 1 (1–6) 1 (1–5) 0.180
FOLFIRI, patients, n (%) 13 (37%) 20 (41%) 15 (29%) 5 (31%) 0.410
Number of cycles, mean (range) 7 (4–35) 6 (2–26) 8 (2–36) 8 (3–20) 0.520
Interval between chemotherapy and surgery, months, mean (range) 1 (1–5) 1 (1–5) 2 (1–6) 1 (1–6) 0.13
Bevacizumab, patients, n (%) 9 (26%) 8 (16%) 3 (6%) 0 0.005 (protective
effect)
Number of cycles, mean (range) 10 (4–16) 8 (6–12) 7 (6–10) – 0.220
Interval between chemotherapy and surgery, months, mean (range) 2 (1–6) 2 (1–3) 3 (2–4) – 0.800
Cetuximab, patients, n (%) 4 (11%) 8 (16%) 5 (10%) 1 (6%) 0.470
Number of cycles, mean (range) 12 (6–18) 6 (2–26) 8 (4–36) 20 0.340
Interval between chemotherapy and surgery, months, mean (range) 2 (1–2) 1 (1–6) 1 (1–2) 1 0.240
5-Fluorouracil, patients, n (%) 0 0 3 (6%) 4 (25%) <0.001
Number of cycles, mean (range) NA NA 8 (6–12) 7 (2–12) 0.480
Interval between chemotherapy and surgery, months, mean (range) NA NA 1 (1–2) 1 (1–2) 0.180
PVE, portal vein embolization; 5-FU, 5-fluorouracil; FOLFOX, folinic acid, 5-FU, oxaliplatin; FOLFIRI, folinic acid, 5-FU, irinotecan; NA, not available.
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patients who received oxaliplatin-based chemotherapy with beva-
cizumab (P = 0.003). Finally, multivariate analysis identified beva-
cizumab as a chemotherapeutic agent that is protective against
SOS lesions (P = 0.004).
Discussion
Chemotherapy-induced liver injury is a problem in patients
undergoing surgery for CRLM, in whom an increase in postop-
Table 2 Univariate analysis of biological predictive factors and sinusoidal obstruction syndrome (SOS) by grade
Preoperative biological variables Group 1 Group 2 Group 3 Group 4 P-value
(SOS grade 0,
n = 35)
(SOS grade 1,
n = 49)
(SOS grade 2,
n = 51)
(SOS grade 3,
n = 16)
Mean (range) Mean (range) Mean (range) Mean (range)
AST (normal: <50 U/l) 25 (15–60) 27 (15–92) 30 (15–274) 32 (21–100) 0.130
ALT (normal: <50 U/l) 26 (14–78) 25 (10–72) 31 (11–277) 30 (19–123) 0.300
AP (normal: 30–120 U/l) 80 (29–218) 99 (36–336) 82 (49–672) 93 (72–220) 0.400
GGT (normal: <50 U/l) 45 (19–195) 51 (10–327) 59 (15–377) 80 (19–377) 0.033
Direct bilirubin (normal: <0.3 mg/dl) 0.1 (0–0.2) 0.1 (0–0.4) 0.1 (0–0.5) 0.1 (0–0.3) 0.018
Platelet count (103) (normal:
150–300 ¥ 103/ml)
272 (171–393) 222 (116–445) 246 (62–484) 197 (94–290) 0.003
Indocyanine green test (normal: <10%) 4.8 (0.1–13.8) 6.9 (0.4–16.7) 7.7 (0.7–34) 10.2 (3.9–34) <0.001
APRI score 0.163 (0.080–0.556) 0.198 (0.068–1.119) 0.265 (0.087–4.529) 0.325 (0.169–0.643) <0.001
Fib-4 score 1.173 (0.580–2.394) 1.504 (0.209–4.157) 1.544 (0.330–6.395) 1.658 (1.045–4.025) <0.001
AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; GGT, g-glutamyl-transferase; APRI, AST : platelet ratio
index.
Platelet count Log indocyanine green test
Log APRI Log FIB-4
SOS grade 0510
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Figure 1 Significant biological factors predictive of sinusoidal obstruction syndrome (SOS) lesions in univariate analysis (Table 2). APRI,
aspartate aminotransferase : platelets ratio index
HPB 861
HPB 2013, 15, 858–864 © 2013 International Hepato-Pancreato-Biliary Association
erative morbidity has been observed.10–12 Patients who are treated
with oxaliplatin-based chemotherapy have been found to display
an increased need for perioperative transfusions,24,25 higher peri-
operative morbidity,11,24,26 especially in major hepatectomies,12,26
and a longer postoperative hospital stay.12,24 These consequences
increase with the number of cycles of chemotherapy adminis-
tered.11,24 Although oxaliplatin-based chemotherapy is the chemo-
therapeutic agent most often incriminated in SOS, the present
authors have previously reported that severe SOS lesions were also
encountered in patients treated with 5-FU or irinotecan-based
chemotherapy.10 In the present study, both oxaliplatin-based
chemotherapy and 5-FU were significantly associated with severe
(grades 2 and 3) SOS lesions. However, the administration of
irinotecan-based chemotherapy was not significantly correlated
with grade 2 and 3 SOS lesions.
Perioperative morbidity and mortality after major hepatec-
tomy are often related to postoperative liver failure. Outcomes
following major liver resection have improved in recent decades,
partially as a result of the better selection and preparation of
patients through the use of preoperative liver volume assessment
and selected use of PVE.12,26–28 However, liver volume is only one
of the criteria to be taken into consideration in the preoperative
strategy to avoid postoperative liver failure. Indeed, the quality of
the liver parenchyma and liver function must also be considered.
Until now, factors predictive of SOS lesions had not been widely
identified. Aloia et al.24 reported an increased rate of GGT in
both the pre- and postoperative periods in patients with SOS.
Nakano et al.12 reported that female gender, the administration of
six or more cycles of oxaliplatin-based chemotherapy, abnormal
preoperative AST values (>36 IU/l) and abnormal preoperative
ICG test values (>10%) were preoperative factors significantly
associated with SOS lesions. In addition, the benefit of a preop-
erative liver needle biopsy to evaluate the severity of SOS in
patients who receive high doses of chemotherapy is uncertain as
a result of the heterogeneous distribution of lesions within the
liver. Indeed, Rubbia-Brandt et al. reported that SOS lesions were
predominantly visible in the subcapsular region, but were hap-
hazardly distributed and affected nodules were intermingled with
intact parenchyma.29 Recently, Soubrane et al.26 reported that a
low preoperative platelet count and a high APRI score were the
most reliable indicators of the severity of SOS, and provided area
under the curve (AUC) values of 0.84 and 0.85, respectively, in
receiver operating characteristic (ROC) analyses. The cut-off
APRI score has been evaluated as 0.36 according to these data.
This score is very interesting because it is readily available (it is
calculated in preoperative laboratory tests including AST serum
level and platelet count) at low cost.
In the present study, univariate analysis showed that direct
bilirubin (P = 0.018), GGT (P = 0.033), platelet count (P = 0.003),
ICG test (P < 0.001), Fib-4 score (P < 0.001) and APRI score (P <
0.001) represent factors that are significantly predictive of severe
SOS. Nodular regenerative hyperplasia is the most severe form of
SOS and describes a proliferative process in which regenerative
nodules replace the normal liver architecture, inducing compres-
sion on the surrounding parenchyma, which exhibits congestion
and sinusoidal dilatation. Portal hypertension (PHT) is com-
monly observed in NRH.9,16 Diffuse NRH is associated with
increased postoperative hepatic morbidity.16 Preoperative factors
predictive of NRH would be very helpful in the detection of these
very high-risk patients. In the present study, ICG test values, APRI
scores and Fib-4 scores were identified as the factors that best
predicted NRH. This contradicts the results of Wicherts et al.,16
who reported non-altered ICG test values in patients with NRH.
The latter authors identified preoperative elevated levels of GGT
and total bilirubin as factors predictive of NRH.16 In the present
study, a minority of patients with NRH (two of five) had abnor-
mal GGT and direct bilirubin values. A low platelet count was
found in 48% of patients with NRH in the series reported by
Wicherts et al.16 and in 40% of patients with NRH in the present
study. This may be explained by platelet trapping related to
splenomegaly caused by PHT.
Overman et al.30 reported an increase in spleen size of50% in
24% of patients treated with FOLFOX [folinic acid (leucovorin),
5-FU, oxaliplatin] correlated with high-grade hepatic sinusoidal
injury at the time of liver resection and with a higher rate of
thrombocytopoenia. In the present series, splenomegaly was also
significantly associated with high-grade (2 and 3) sinusoidal
lesions and with a low platelet count.
Secondly, data from the present study, like those reported pre-
viously,4,29 corroborate the protective effect of bevacizumab in
reducing the incidence of SOS lesions significantly. The mecha-
nism by which this protective effect is engaged remains unclear.
Many authors have reported that the preoperative administration
of bevacizumab does not increase postoperative morbidity in
patients undergoing liver surgery for CRLM,31–33 provided that
6–8 weeks are allowed to elapse between the end of bevacizumab
administration and liver surgery. Additionally, bevacizumab
has also been reported to have a protective clinical impact on
Table 3 Occurrence of sinusoidal obstruction syndrome (SOS) by grade in patients treated with oxaliplatin with and without bevacizumab
Oxaliplatin alone
(n = 67)
Oxaliplatin + bevacizumab
(n = 10)
P-value
Group 1 (SOS grade 0, n = 35), n 7 4 0.003
Group 2 (SOS grade 1, n = 49), n 23 5
Group 3 (SOS grade 2, n = 51), n 28 1
Group 4 (SOS grade 3, n = 16), n 9 0
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postoperative liver failure after liver resection and on the inci-
dence of SOS lesions.4,34
In conclusion, as the present authors have previously
reported,10 severe SOS lesions occurred in patients who received
oxaliplatin-based chemotherapy and 5-FU chemotherapy. Uni-
variate analysis identified APRI score as the most significant bio-
logical factor predictive of severe SOS lesions. Splenomegaly is
also significantly associated with the occurrence of severe SOS
lesions and/or NRH. Finally, bevacizumab has a protective effect
against SOS lesions.
Special attention should be given to patients who have been
treated with oxaliplatin-based chemotherapy without bevacizu-
mab who present preoperatively with a low platelet count, an
APRI score of >0.36 and/or splenomegaly because these individu-
als are at risk for severe SOS lesions. In such patients in whom
major hepatectomy is planned, particular attention should be
given to preoperative preparation according to liver sector volum-
etry in order that more liberal right PVE can be planned.
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